NTRA - Natera, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
San Carlos,
United States
Type: Equity
NTRA price evolution
NTRA
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $796.8 | $813.82 | $642.1 | |
| Short term investments | $90.3 | $69.12 | $236.88 | |
| Net receivables | $306.88 | $335.94 | $288.75 | $278.29 |
| Inventory | $48.72 | $40.98 | $43.02 | $40.76 |
| Total current assets | $1322.57 | $1301.82 | $1261.44 | $1258.55 |
| Long term investments | ||||
| Property, plant & equipment | $230.03 | $185.86 | $180.34 | $167.75 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $215.17 | $206.76 | $183.15 | |
| Total investments | $90.3 | $69.12 | $236.88 | |
| Total assets | $1590.95 | $1516.99 | $1468.2 | $1441.7 |
| Current liabilities | ||||
| Accounts payable | $27.83 | $33.1 | $26.04 | $15 |
| Deferred revenue | $39.43 | $38.42 | $35.74 | |
| Short long term debt | $80.39 | $80.4 | $80.4 | |
| Total current liabilities | $301.42 | $314.57 | $305.95 | $307.27 |
| Long term debt | $286.55 | $344.83 | $347.43 | $349.97 |
| Total noncurrent liabilities | $365.89 | $368.14 | $369.1 | |
| Total debt | $425.22 | $427.83 | $430.37 | |
| Total liabilities | $712.42 | $680.47 | $674.09 | $676.37 |
| Shareholders' equity | ||||
| Retained earnings | -$2514.09 | -$2482.5 | -$2445.03 | -$2377.44 |
| Other shareholder equity | -$0.77 | -$1.36 | -$2.19 | -$3.08 |
| Total shareholder equity | $836.52 | $794.11 | $765.33 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $642.1 | $466.09 | $84.61 | $48.85 |
| Short term investments | $236.88 | $432.3 | $829.9 | $688.61 |
| Net receivables | $278.29 | $244.38 | $122.07 | $78.56 |
| Inventory | $40.76 | $35.41 | $26.91 | $20.03 |
| Total current assets | $1258.55 | $1211.82 | $1093.14 | $862.66 |
| Long term investments | ||||
| Property, plant & equipment | $167.75 | $164.33 | $124.53 | $54.75 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $183.15 | $182.66 | $143.35 | $69.49 |
| Total investments | $236.88 | $432.3 | $829.9 | $688.61 |
| Total assets | $1441.7 | $1394.47 | $1236.49 | $932.15 |
| Current liabilities | ||||
| Accounts payable | $15 | $31.15 | $27.21 | $8.1 |
| Deferred revenue | $35.74 | $30.78 | $28.72 | $72.93 |
| Short long term debt | $80.4 | $80.35 | $50.05 | $50.05 |
| Total current liabilities | $307.27 | $310.5 | $218.96 | $199.05 |
| Long term debt | $349.97 | $281.65 | $341.43 | $223.74 |
| Total noncurrent liabilities | $369.1 | $378.23 | $364.23 | $246.86 |
| Total debt | $430.37 | $438.58 | $391.48 | $273.79 |
| Total liabilities | $676.37 | $688.73 | $583.18 | $445.92 |
| Shareholders' equity | ||||
| Retained earnings | -$2377.44 | -$1942.63 | -$1394.84 | -$929.32 |
| Other shareholder equity | -$3.08 | -$16.36 | -$2.29 | $4.26 |
| Total shareholder equity | $765.33 | $705.74 | $653.3 | $486.24 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 1 May 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $413.35 | $311.11 | ||
| Cost of revenue | $170.18 | $151.25 | ||
| Gross Profit | $243.17 | $159.86 | ||
| Operating activities | ||||
| Research & development | $89.11 | $82.96 | ||
| Selling, general & administrative | $197.97 | $161.43 | ||
| Total operating expenses | $287.07 | $244.39 | ||
| Operating income | -$43.9 | -$84.54 | ||
| Income from continuing operations | ||||
| EBIT | -$33.45 | -$74.69 | ||
| Income tax expense | $0.89 | $0.19 | ||
| Interest expense | $3.13 | $3.15 | ||
| Net income | ||||
| Net income | -$37.46 | -$78.03 | ||
| Income (for common shares) | -$37.46 | -$78.03 | ||
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1082.57 | $820.22 | $625.49 | $391 |
| Cost of revenue | $589.83 | $456.26 | $318.42 | $203.62 |
| Gross Profit | $492.74 | $363.97 | $307.07 | $187.38 |
| Operating activities | ||||
| Research & development | $320.68 | $316.42 | $264.21 | $100.03 |
| Selling, general & administrative | $618.31 | $588.59 | $511.03 | $303.63 |
| Total operating expenses | $938.99 | $905.01 | $775.24 | $403.66 |
| Operating income | -$446.25 | -$541.04 | -$468.17 | -$216.28 |
| Income from continuing operations | ||||
| EBIT | -$421.89 | -$537.5 | -$462.79 | -$214.56 |
| Income tax expense | $0.27 | $0.98 | $0.62 | $0.1 |
| Interest expense | $12.64 | $9.32 | $8.3 | $15.08 |
| Net income | ||||
| Net income | -$434.8 | -$547.8 | -$471.72 | -$229.74 |
| Income (for common shares) | -$434.8 | -$547.8 | -$471.72 | -$229.74 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$37.46 | -$67.6 | -$78.03 | |
| Operating activities | ||||
| Depreciation | $11.53 | $10.66 | $10.42 | |
| Business acquisitions & disposals | $10.49 | -$10.49 | ||
| Stock-based compensation | $67.41 | $64.45 | $48.91 | |
| Total cash flows from operations | $3.99 | $27 | -$58.13 | |
| Investing activities | ||||
| Capital expenditures | -$11.68 | -$20.32 | -$9.53 | |
| Investments | -$20.38 | $169.06 | $34.2 | |
| Total cash flows from investing | $148.74 | -$32.05 | $138.25 | $24.66 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $11.04 | $6.47 | $6.84 | |
| Net borrowings | ||||
| Total cash flows from financing | $19.23 | $11.04 | $6.47 | $6.84 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $250.75 | -$17.02 | $171.72 | -$26.61 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$434.8 | -$547.8 | -$471.72 | -$229.74 |
| Operating activities | ||||
| Depreciation | $38.62 | $30.47 | $22.18 | $16.45 |
| Business acquisitions & disposals | -$8.56 | |||
| Stock-based compensation | $191.81 | $152.38 | $115.22 | $50.17 |
| Total cash flows from operations | -$246.96 | -$431.5 | -$335.24 | -$182.51 |
| Investing activities | ||||
| Capital expenditures | -$39.2 | -$47.7 | -$41.03 | -$19.6 |
| Investments | $207.7 | $378.04 | -$155.6 | -$311.86 |
| Total cash flows from investing | $168.5 | $330.34 | -$205.19 | -$331.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $254.46 | $452.64 | $576.19 | $301.29 |
| Net borrowings | $30 | $199.56 | ||
| Total cash flows from financing | $254.46 | $482.64 | $576.19 | $500.85 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $176 | $381.48 | $35.76 | -$13.13 |
News
|
Here’s Why Natera (NTRA) Surged in Q4
Insider Monkey · via Yahoo Finance
28 Jan 2025
|
|
Natera's president sells $3.5 million in stock By Investing.com
Investing.com
25 Jan 2025
|
|
Natera's CFO Michael Burkes sells $247,378 in stock By Investing.com
Investing.com
25 Jan 2025
|
|
Natera president sells $4.1 million in stock By Investing.com
Investing.com
25 Jan 2025
|
|
Natera's CFO Michael Burkes sells $247,378 in stock By Investing.com
Investing.com
25 Jan 2025
|
|
Wednesday’s Insider Activity: Top Buys and Sells in US Stocks Revealed By...
Investing.com
23 Jan 2025
|
|
Natera's chief legal officer sells $3.64 million in stock By Investing.com
Investing.com
23 Jan 2025
|
|
Natera CEO Steven Chapman sells $12.96m in stock By Investing.com
Investing.com
23 Jan 2025
|
|
Natera co-founder Sheena Jonathan sells $160,214 in stock By Investing.com
Investing.com
23 Jan 2025
|
|
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Zacks · via Yahoo Finance
22 Jan 2025
|
Fundamentals
| Market cap | $23.53B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 124.14M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.88 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 4.39 |
| Quick ratio | 4.23 |